• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, November 20, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Model Projects $36.6M Savings From cfRNA Preeclampsia Screening

by
November 20, 2026
in Health
Reading Time: 6 mins read
0
Model Projects $36.6M Savings From cfRNA Preeclampsia Screening

Model Projects $36.6M Savings From cfRNA Preeclampsia Screening

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A new budget impact model published in PharmacoEconomics – Open projects that a cell-free RNA (cfRNA) test-and-treat strategy for preeclampsia could generate first-year net health plan savings of $36.6 million per 10,000 eligible advanced maternal age pregnancies. The study, authored by April Zambelli-Weiner, Brian Nathanson, and Susan Hahn, evaluates the economic implications of replacing current United States Preventive Services Task Force (USPSTF) risk-based screening with a biomarker-guided approach. The analysis focuses specifically on singleton pregnancies in women aged 35 or older who do not have pre-existing high-risk conditions such as chronic hypertension or diabetes. By simulating the financial outcomes of this targeted intervention, the researchers aim to provide payers with a clearer understanding of the potential cost-effectiveness of personalized preeclampsia prevention.

Preeclampsia affects approximately 8% of pregnancies in the United States and remains a leading cause of maternal and neonatal morbidity and mortality. The condition can lead to severe complications, including organ dysfunction, eclampsia, and HELLP syndrome, for the mother, while significantly increasing the risk of preterm birth for the infant. Up to 44% of preeclamptic pregnancies result in preterm delivery, which subjects newborns to complications such as respiratory distress syndrome and long-term disability. Despite the severity of these outcomes, current screening methods rely heavily on clinical risk factors and have limited specificity, often failing to accurately identify which patients are at the highest risk for severe disease.

The study utilized a deterministic budget impact model developed from the perspective of a US commercial payer. The model simulated a hypothetical health plan with 4.5 million members and 10,000 eligible advanced maternal age pregnancies annually. It compared two distinct care pathways: the current standard of care based on USPSTF guidelines and a new strategy involving cfRNA testing followed by targeted preventive management. The cfRNA test, which analyzes cell-free RNA in maternal blood between 18 and 22 weeks of gestation, was assumed to provide highly personalized risk predictions. In the model, pregnancies identified as high-risk through this test received targeted interventions, including low-dose aspirin prophylaxis and enhanced surveillance.

Clinical performance inputs for the model were derived from published data, which indicated that the cfRNA test achieved 91% sensitivity and 74% specificity for detecting preterm preeclampsia in the target population. In comparison, the USPSTF guidelines achieved the same sensitivity but with a much lower specificity of 22%. This difference in specificity is crucial because it suggests that the cfRNA test could more accurately identify women who truly need intensive preventive measures, thereby avoiding the overidentification of risk that is common with current broad clinical criteria. The model also incorporated data from the ASPRE trial to estimate the effectiveness of low-dose aspirin in reducing the risk of early-onset and preterm preeclampsia among treated patients.

The base-case results of the model showed that the cfRNA test-and-treat strategy was projected to reduce both maternal and infant healthcare payments compared to the current standard of care. Using net plan payments, which represent the amount paid directly by the health plan, the projected first-year net savings were $36.6 million per 10,000 eligible pregnancies. On a total allowed-payment basis, which includes both insurer-paid amounts and patient cost-sharing, the projected first-year net budget savings were slightly higher at $37.4 million. These savings were driven primarily by a reduction in high-cost clinical events, particularly early preterm deliveries and the associated need for neonatal intensive care unit (NICU) admissions.

The model projected that the cfRNA strategy would reduce the total number of preeclampsia cases from 790 to 708 per 10,000 pregnancies, representing a decrease from 8% to 7%. More significantly, among pregnancies that did develop preeclampsia, the strategy was projected to shift the timing of delivery to a later gestational age. This shift resulted in a substantial reduction in preterm preeclampsia cases, with the largest declines observed in early preterm births before 34 weeks. The prevention of these early deliveries was the primary driver of the economic savings, as it translated to an estimated prevention of approximately 7,777 NICU days per 10,000 pregnancies tested.

Over a five-year horizon, the projected savings increased as the model accounted for annual implementation across successive pregnancy cohorts. Using net plan payments, the projected net health plan savings increased from $36.6 million in the first year to $56.1 million in the fifth year. The cumulative net savings over the five-year period were estimated at $229.8 million. These long-term projections suggest that the financial benefits of the cfRNA strategy could grow over time, potentially offsetting the initial costs of testing and implementation. The model also calculated a return on investment (ROI) of 3.00:1 on a total allowed-payment basis, indicating that for every dollar spent on the testing and intervention strategy, the health plan could save three dollars in avoided clinical costs.

Scenario and sensitivity analyses were conducted to evaluate the robustness of these findings under various assumptions. The researchers tested different rates of preeclampsia incidence growth, alternative aspirin doses, and the inclusion of remote blood pressure monitoring costs. The results remained favorable across most scenarios, with the ROI staying above 3:1 in many cases. However, the analysis highlighted that the projected savings are highly sensitive to assumptions regarding medication adherence and clinical recommendation rates. If providers do not consistently recommend aspirin or if patients do not adhere to the prescribed regimen, the economic benefits of the cfRNA strategy could be significantly diminished. This underscores the importance of behavioral changes in clinical practice for the success of the intervention.

The study acknowledges several limitations inherent in its design. First, the model relies on assumptions about clinical performance and downstream management effects that may vary across different workflows and payer environments. Second, the behavioral improvements in adherence and recommendation rates were structural assumptions rather than effects demonstrated in a prospective implementation study. The authors note that while the cfRNA test is clinically validated for risk identification, the specific economic benefits projected in this model depend on the successful integration of this test into routine prenatal care. Furthermore, the results are specific to the commercial payer perspective and may not generalize to Medicaid or uninsured populations, which have different risk factor prevalences and reimbursement structures.

Despite these limitations, the findings suggest that cfRNA-based screening could be a valuable tool for improving preeclampsia prevention in advanced maternal age pregnancies. By providing more accurate risk stratification, the test-and-treat strategy has the potential to reduce the burden of severe preeclampsia and its associated healthcare costs. The authors recommend that these modeled estimates be interpreted with caution and that further prospective real-world validation studies are needed to confirm the clinical and economic benefits of this approach. As the prevalence of preeclampsia continues to rise, the development of more precise screening tools may be essential for optimizing maternal and neonatal outcomes in the United States.

Current clinical guidelines from the USPSTF direct clinicians to assess preeclampsia risk by evaluating demographic traits, medical history, and clinical factors during routine prenatal visits. Under this standard framework, pregnant individuals identified with one high-risk factor or multiple moderate-risk factors—such as advanced maternal age, nulliparity, or obesity—are recommended to initiate low-dose aspirin prophylaxis between 12 and 28 weeks of gestation, ideally before 16 weeks. However, implementation barriers remain substantial in everyday obstetric practice. Only 24% to 37% of healthcare providers routinely recommend aspirin to individuals presenting with moderate-risk factors, and patient adherence rates remain below 25%, meaning fewer than 10% of eligible pregnant individuals actually take preventive aspirin.

The economic analysis established base-case testing costs at $1,865 per eligible pregnancy, reflecting the commercial list price for the test kit, phlebotomy, shipping, and laboratory processing. Post-test preventive intervention costs, encompassing low-dose aspirin prophylaxis and targeted clinical management, were estimated at $18.78 per woman identified as high risk. Because aspirin acquisition costs represent a negligible fraction of overall maternal and neonatal healthcare expenditures, the model incorporated a daily aspirin regimen of 162 mg to align conservatively across study arms without adding separate outpatient visit costs. Unit expenditure estimates were standardized to 2024 US dollars using the Medical Care Consumer Price Index based on claims data from 3,357 preeclampsia maternal–infant dyads and 18,278 matched control dyads.

Extending these projections across national demographic data illustrates the potential public health scale of targeted screening. Data from the National Center for Health Statistics show that advanced maternal age accounts for 21% of all live births in the United States, representing approximately 774,908 annual deliveries. Applying the model’s eligibility fraction of 81.5% identifies roughly 632,000 eligible pregnancies each year. At that national scale, the modeled gross clinical-event savings of $56.1 million per 10,000 tested pregnancies would yield approximately $3.5 billion in annual gross savings. Researchers emphasize that these modeled estimates represent potential economic returns under specific adherence assumptions, requiring confirmation through prospective real-world implementation studies currently underway.

Subject of Research: Budget impact of cfRNA test-and-treat strategy for preeclampsia in advanced maternal age pregnancies

Article Title: Budget Impact Model of a Novel cfRNA Test-and-Treat Strategy for Preeclampsia in Advanced Maternal Age Pregnancies Compared with Current Guidelines

Article References: Zambelli-Weiner, A., Nathanson, B., & Hahn, S. (2026). Budget Impact Model of a Novel cfRNA Test-and-Treat Strategy for Preeclampsia in Advanced Maternal Age Pregnancies Compared with Current Guidelines. PharmacoEconomics – Open, 10(6), 1117-1133. https://doi.org/10.1007/s41669-026-00682-7

Image Credits: AI Generated

DOI: 10.1007/s41669-026-00682-7

Keywords: preeclampsia, cfRNA testing, budget impact model, advanced maternal age, USPSTF guidelines, low-dose aspirin, neonatal intensive care, health plan savings, preterm birth, maternal health, risk stratification, commercial payer, prenatal screening, clinical outcomes, pharmacoeconomics

News Source: Harold Sullivan. (November 20, 2026). Model Projects $36.6M Savings From cfRNA Preeclampsia Screening. Scienmag.

Tags: advanced maternal agebudget impact modelcfRNA testingclinical outcomescommercial payerhealth plan savingsLow-dose aspirinMaternal Healthneonatal intensive carepharmacoeconomicspreeclampsiaprenatal screeningPreterm Birthrisk stratificationUSPSTF guidelines
Share12Tweet7Share2ShareShareShare1

Related Posts

Ultrasound Guided Forearm Nerve Blocks Prove Feasible in Ambulatory Hand Surgeries

Ultrasound Guided Forearm Nerve Blocks Prove Feasible in Ambulatory Hand Surgeries

November 20, 2026
Neural Progenitor Adhesion Weakening Drives Congenital Hydrocephalus in Mouse Models

Neural Progenitor Adhesion Weakening Drives Congenital Hydrocephalus in Mouse Models

November 20, 2026

Smartwatch Monitoring Exposes Frequent Clinical Walking Assessment Flaws in Multiple Sclerosis

November 20, 2026

Serum Annexin-A1 Levels Predict Acute Kidney Injury Following Cardiac Surgery

November 20, 2026

POPULAR NEWS

  • Chemical and Microbial Feedback Loops Drive Soil Sickness in Medicinal Crops

    Chemical and Microbial Feedback Loops Drive Soil Sickness in Medicinal Crops

    29 shares
    Share 12 Tweet 7
  • National Survey Reveals Significant Digital Gaps Among Groups Facing Oral Health Inequities

    29 shares
    Share 12 Tweet 7
  • Review Evaluates Strategies to Prevent and Treat Mandibular Nerve Injury During Jaw Surgery

    29 shares
    Share 12 Tweet 7
  • Dental Sector Dominates Japan’s Regional Outpatient Dysphagia Rehabilitation Claims

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Ultrasound Guided Forearm Nerve Blocks Prove Feasible in Ambulatory Hand Surgeries

Neural Progenitor Adhesion Weakening Drives Congenital Hydrocephalus in Mouse Models

Smartwatch Monitoring Exposes Frequent Clinical Walking Assessment Flaws in Multiple Sclerosis

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.